You may have additional questions before making the decision to participate in the NEW DAY Study.
Many of the answers to your questions can be found at www.clinicaltrials.gov, however, below we have also summarized some of the more frequently asked questions.
What is the purpose of the NEW DAY Study?
It is the first randomized, controlled trial that will compare anti-VEGF therapy to a long-acting corticosteroid, fluocinolone acetonide, as a first-line, baseline therapy for treatment of diabetic macular edema (DME). The trial will target approximately 300 patients in approximately 40 U.S. clinical trial study centers.
How long does the study last?
If you qualify and agree to participate, you will be asked to commit 18 months to the study.
What is the time commitment for this study?
The NEW DAY Study requires a monthly visit to your doctor’s office for the duration of the study (at least 18 months).
Will I be compensated for participating in this study?
Eligible participants may be compensated for their time and travel.
What COVID-19 protocols do you have in place?
Your safety is our first priority during this study. Every doctor will have the necessary protocols in place to ensure safe participation.